Risk characteristics of obesity and atherosclerotic cardiovascular events in patients with schizophrenia: A single-center 10-year retrospective cohort study

doi:10.5498/wjp.v16.i4.114138

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

(41)

(31)

(0)

(8)

(670)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Psychiatry. Apr 19, 2026; 16(4): 114138
Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.114138

Table 3 Antipsychotic medication use patterns at our hospital at baseline, mean ± SD

Medication pattern	n (%)	Mean daily dose (CPZ equivalents)	Duration at our facility (years)
Treatment regimen
Monotherapy	5432 (54.3)	423 ± 234	4.3 ± 3.8
Polypharmacy (2 agents)	2456 (24.6)	612 ± 298	3.8 ± 3.2
Polypharmacy (≥ 3 agents)	846 (8.5)	834 ± 367	3.2 ± 2.9
No current antipsychotic	1266 (12.7)	-	-
Specific agents
Olanzapine	2134 (21.3)	489 ± 189	4.8 ± 4.1
Risperidone	1987 (19.9)	398 ± 156	4.2 ± 3.6
Quetiapine	1543 (15.4)	445 ± 234	3.9 ± 3.4
Aripiprazole	1234 (12.3)	367 ± 145	3.2 ± 2.8
Paliperidone	987 (9.9)	412 ± 178	2.8 ± 2.4
Clozapine	678 (6.8)	523 ± 212	5.6 ± 4.8
Haloperidol	567 (5.7)	389 ± 167	3.4 ± 3.1
Other	1604 (16.0)	401 ± 189	3.6 ± 3.2
Metabolic risk category
High risk	3890 (38.9)	478 ± 223	4.6 ± 3.9
Moderate risk	2987 (29.9)	412 ± 187	3.8 ± 3.3
Low risk	1857 (18.6)	378 ± 156	3.1 ± 2.7

CPZ: Chlorpromazine.

Full Size Table

Citation: Long JF, Deng LM, Zhang JD, Tang ZJ, Zhou K. Risk characteristics of obesity and atherosclerotic cardiovascular events in patients with schizophrenia: A single-center 10-year retrospective cohort study. World J Psychiatry 2026; 16(4): 114138
URL: https://www.wjgnet.com/2220-3206/full/v16/i4/114138.htm
DOI: https://dx.doi.org/10.5498/wjp.v16.i4.114138

Long JF, Deng LM, Zhang JD, Tang ZJ, Zhou K. Risk characteristics of obesity and atherosclerotic cardiovascular events in patients with schizophrenia: A single-center 10-year retrospective cohort study. World J Psychiatry 2026; 16(4): 114138 [DOI: 10.5498/wjp.v16.i4.114138]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.